TY - JOUR
T1 - Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases
AU - Fanetti, Giuseppe
AU - Marvaso, Giulia
AU - Ciardo, Delia
AU - Rese, Annaisabel
AU - Ricotti, Rosalinda
AU - Rondi, Elena
AU - Comi, Stefania
AU - Cattani, Federica
AU - Zerini, Dario
AU - Fodor, Cristiana
AU - de Cobelli, Ottavio
AU - Orecchia, Roberto
AU - Jereczek-Fossa, Barbara A.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - To evaluate outcome in patients treated with stereotactic body radiotherapy (SBRT) on bone oligometastases from castration-sensitive prostate cancer after primary treatment. We retrospectively collected data of patients with less than five lesions at time of SBRT and hormone-naïve disease at the first extra-regional localization, treated between 03/2012 and 11/2016. Prostate-specific antigen (PSA) was measured every 3 months after SBRT. Imaging was performed in case of progression. Survival analysis was performed with Kaplan–Meier (log-rank test) approach. Fifty-five patients were treated on 77 bone oligometastases. Median age, initial PSA and pre-SBRT PSA were 72 years, 9.12 and 3.5 ng/mL, respectively. Twenty-five patients (45%) received SBRT alone while the remaining 30 patients (55%) received concomitant ADT. Median follow-up was 24.6 months (range 3.0–67.2 months). No acute or late toxicity of grade > 1 was reported. Clinical progression was observed in 38 (69%) patients. 1-year biochemical progression-free survival (b-PFS), clinical progression-free survival (c-PFS), prostate-specific survival (PCSS) and local control (LC) rates were 51, 56, 100 and 83%, respectively. Comparing patients treated with SBRT alone and with concomitant ADT, no significant differences were found for those outcomes. SBRT is safe and allows high 1-year LC rate (83%) with low toxicity profile. No significant improvement in outcomes was registered with the addition of ADT to SBRT.
AB - To evaluate outcome in patients treated with stereotactic body radiotherapy (SBRT) on bone oligometastases from castration-sensitive prostate cancer after primary treatment. We retrospectively collected data of patients with less than five lesions at time of SBRT and hormone-naïve disease at the first extra-regional localization, treated between 03/2012 and 11/2016. Prostate-specific antigen (PSA) was measured every 3 months after SBRT. Imaging was performed in case of progression. Survival analysis was performed with Kaplan–Meier (log-rank test) approach. Fifty-five patients were treated on 77 bone oligometastases. Median age, initial PSA and pre-SBRT PSA were 72 years, 9.12 and 3.5 ng/mL, respectively. Twenty-five patients (45%) received SBRT alone while the remaining 30 patients (55%) received concomitant ADT. Median follow-up was 24.6 months (range 3.0–67.2 months). No acute or late toxicity of grade > 1 was reported. Clinical progression was observed in 38 (69%) patients. 1-year biochemical progression-free survival (b-PFS), clinical progression-free survival (c-PFS), prostate-specific survival (PCSS) and local control (LC) rates were 51, 56, 100 and 83%, respectively. Comparing patients treated with SBRT alone and with concomitant ADT, no significant differences were found for those outcomes. SBRT is safe and allows high 1-year LC rate (83%) with low toxicity profile. No significant improvement in outcomes was registered with the addition of ADT to SBRT.
KW - Androgen deprivation therapy
KW - Bone metastases
KW - Castration-sensitive prostate cancer
KW - Oligometastases
KW - Prostate cancer
KW - Stereotactic body radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85045729169&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045729169&partnerID=8YFLogxK
U2 - 10.1007/s12032-018-1137-0
DO - 10.1007/s12032-018-1137-0
M3 - Article
C2 - 29671075
AN - SCOPUS:85045729169
VL - 35
JO - Medical Oncology
JF - Medical Oncology
SN - 1357-0560
IS - 5
M1 - 75
ER -